ally between 50-360 J, via two electrodes (paddles). A transthoracic direct current shock of sufficient magnitude depolarises the entire myocardium, rendering the entire heart momentarily refractory to repeat depolarisation. Thereafter, the most rapid intrinsic pacemaker, usually the sinoatrial node, reassumes control of heart rhythm (Sucu et al,. 2009 ).
Direct current cardioversion (DCCV) can be considered as an urgent and optional method for restoring sinus rhythm in patients with AFib (Kirchhof et al., 2007) .
Anticoagulants are considered mandatory before scheduled cardioversion in atrial fibrillation, if it lasts more than 48 hours or if the duration of the episode is not known. Because of the increased risk of cardiovascular thromboembolic events, the European Society of Cardiology 2016 guidelines recommend using anticoagulants at least three weeks before and four weeks after the procedure (ECV) (Weinberg et al., 1989; Nuotio et al., 2014; Kirchhof et al., 2016) . Patients without therapeutic anticoagulation have a post-procedural thromboembolic risk of 5-7% (Arnold et al., 1992) .
Depending on the source, the frequency of recurrence of AFib after an electrical cardioversion ranges from 40-60%. Adequate antiarrhythmic therapy does not always affect the frequency of recurrence. There are several risk factors that can influence the frequency of recurrences after ECV, such as age, AFib duration, left ventricular size, etc. (Cannon et al., 2008) .
Our goal was to analyse the risk factors of developing recurrence of atrial fibrillation. We assessed the most commonly used medications after an electrical cardioversion and the reasons for not using them as well as the effects of pharmacotherapy on recurrence rate. Finally our aim was to compare the acquired results with data from studies in 2014.
METHODS
The prospective study was conducted between January and August 2017 at the Latvian Centre of Cardiology, Pauls Stradiòð Clinical University Hospital. The study included 168 patients undergoing scheduled or emergency electrical cardioversion. Patients were hospitalised due to electrocardiographically detected atrial fibrillation either by general practitioner or emergency service. Electrocardiograms were re-acquired at the department where the patient was hospitalised. An authorisation of the Ethics Committee of Rîga Stradiòð University was received. Before the questionnaire, all patients received informative material with a description of the research (in Latvian and Russian). Acquainting with it, all patients provided written consent. An anonymous patient questionnaire was used. Contact information of patients and their relatives as well as demographic data (age, gender) were acquired. Information about the type of admittance at the treatment facility, previous history and duration of AFib, history of AFib associated medication use and previous electrical cardioversion was collected. Medical records provided information about the outcome of electrical cardioversion, history of disease and biochemical parameters from blood tests. Based on the collected data, CHA2DS2-VASc was calculated.
The second questionnaire was developed as a telephone survey for patient control after three and six months. The following questions were asked during telephone interviews: if there has been repeated hospitalisation and the cause for it, recurrence of AFib paroxysms (how many times, type of treatment), drugs used for rhythm control and anticoagulation, an adverse drug reactions. In the case of death, detailed information was gathered from relatives about the cause and treatment previously used by the patient.
The study included patients, aged 31 to 84 years. The average age was 64.6 years (±10.5). Among the 168 patients interviewed, 50.0% were female. 18 (10.6%) patients were admitted to the hospital by emergency service, while 140 (83.4%) patients were referred by a general practitioner or a cardiologist. In 10 (6.0%) cases patients admitted themselves. The duration of AFib paroxysism was less than 24 hours in 2 (1.2%) cases, 24 to 48 hours in 8 (4.8%), 48 hours to seven days in 12 (7.1%) and more than seven days in 74 (44.0% ) cases. Seventy-two (42.9%) patients could not report when the paroxysm had started. One hundred and twelve (66.7%) had a history of previous AFib.
Previously, medical cardioversion had been used in 126 (75.0%) patients and ECV was performed in 66 (39.3%) patients. Patient baseline characteristics are summarised in Table 1.
CHA2DS2-VASc was calculated: 12 (7.1%) patients had 0 points, 27 (16.1%) had 1 point and 129 (76.8%) had 2 or more points. The average score was 2.75. The results of patient thromboembolic risk assessment with the CHA2DS2-VASc scale are summarised in Table 2 
RESULTS
Prior to ECV, amiodarone was used in 80 (47.6%) patients. IC group antiarrhythmic drugs were used in 24 (14.2%), and sotalol was used in 6 (3.5%), Beta blockers (BB) were used in 122 (72.6%), while 78 (46.4%) patients used angiotensin converting enzyme inhibitors (ACEI) inhibitors or angiotensin receptor blockers (ARB). The choice of oral anticoagulants before direct current cardioversion (DCCV) was: warfarin in 44 (26.2%) patients, Xarelto (rivaroxaban) in 64 (38.1%) and Pradaxa (dabigatran) in 42 (25.0%). Two (2.4%) patients were using aspirin, while 6 (3.6%) patients were on dual therapy (combination of an anticoagulant and aspirin).
After six months, three patients had died. The cause of death in all three patients was stroke. One patient did not use anticoagulants, but two of three patients used rivaroxaban and warfarin.
Sixty-two (36.9%) patients had one repeated episode of AFib and 20 (11.9%) had a repeated episode two or more times. A total of 82 (48.8%) patients had at least one episode of AFib over a period of six months. Fourty-eight (28.6%) patients were hospitalised due to arrhythmia, six (3.6%) due to pacemaker implantation, two (1.2%) due to scheduled radiofrequency ablation (RFCA), four (2.4%) due to coronary artery bypass grafting (CABG), two (1.2%) due to primary coronary intervention (PCI) and two patients was hospitalised due to acute decompensated heart failure. Reasons for hospitalisation six months after electrocardioversion are summarised in Figure 1 . In 38 (22.6%) patients arrhythmia was discontinued by ECV, eight (4.8%) were treated with medications and in 36 (21.4%) the arrhythmia was not treated at all. Of those patients who did not use oral anticoagulants (OAC) after six months, 24 (85.7%) had CHADS-VASc of two or more. 77.1% of those using aspirin also had CHADS-VASc of two or more. A total of 29.6% were not using OAC despite indications.
Observed adverse reactions after six months were: six (3.6%) patients reported nausea, four (2.4%) had minor bleeding, six (3.6%) patients had cough and six (3.6%) patients reported having had oedema.
Without statistical significance, recurrence of AFib was more frequent in women vs men (60% vs 43%), in patients with diabetes vs without diabetes (56% vs 49%), congestive heart failure vs patients without congestive heart failure (60% vs 47%) and smokers vs non smokers (75% vs 49% 0.02) (Fig. 2) . However, in this study we did not include patients who were enrolled in another study comparing a combination of etacizine and beta-blockers to amiodarone.
DISCUSSION
The incidence of cardiovascular risk factors in the study population was consistent with world literature (Pisters et al., 2012; Femia et al., 2017) .
Most of the patients (83.3%) in the study population were admitted for a scheduled ECV. 42% of patients could not report the time of onset of AFib paroxysms as they were asymptomatic. Literature data (Xiong et al., 2015) show that around 40% of patients with AFib are asymptmatic, which conforms with the data obtained by our study. Patients had found out about their condition while undergoing routine check-ups. The frequency of recurrence of atrial fibrillation in patients after six months corresponds to world literature (Femia et al., 2017) . After six months, 64 (38.0%) patients had been hospitalised, and for 48 (28.6%) patients the cause of hospitalisation was arrhythmia. The rest of patients were hospitalised mainly due to scheduled procedures.
After a six-month follow-up, three patients had died of stroke, of whom two were on oral anticoagulants (warfarin and rivaroxaban). Both patients had a high risk of thromboembolic events (CHA2DS2-VASc ³ 2). The guidelines of the European Society of Cardiology determine that the optimal INR for patients with non-valvular AFib is 2.0-3.0. According to world literature, roughly 40% of patients reach the optimal INR succesfully. Achieving the goal can be complicated by drug interactions and diet mistakes (Kirchhof et al., 2016) . This might have affected the INR of the patients receiving oral anticoagulation hence resulting in an INR below the therapeutic standard. The bioavailability of Xarelto (rivaroxaban) 15 mg and 20 mg is significantly reduced by 44% when taken on an empty stomach. (Stampfuss et al., 2013; Heidbuchel et al., 2017) . Our study found that approximately 30% of patients were taking Xarelto on an empty stomach, which increases the risk of thromboembolic events. (Kirchhof et al., 2016) . There are several reasons for the increse in use of aspirin over time. One is the misinformation of general practitioners, which leads to prescribing aspirin as an alternative for patients who are not financially able to buy DOACs or have difficulties controlling INR. The second reason is lack of general knowledge among patients about their condition, which leads to being easily influenced by misleading information about use of aspirin as an alternative and adequate treatment.
Previous studies showed that the use of anticoagulants after six months increased by 11.6%, respectively. DOACs was the biggest contributor to the rise in anticoagulant use. The use of DOACs versus warfarin increased from 1 : 3 (11.2% vs 35.1%) to 1 : 1 (29.9% vs 28.0%). Change in the use of antithrombotic therapy six months after electrocardioversion over a period of four years are summarised in Figure 3 . This ratio of DOACs and warfarin complies with data from other studies ( Olesen et al., 2015) . The use of aspirin after ECV decreased by 15.7% over six months, respectively. When comparing data over a period of time, the use of aspirin decreases, but remains high. This leads to additional concerns, because 77.1% of patients taking aspirin had a CHA2DS2-VASc > 2 and were not protected from thromboembolism.
Previous studies (Strelnieks et al., 2014) showed that the use of amiodarone has decreased by 7.5%, while the use of etacizine has increased by 4.3%. decreased by 24.8%. The fall in use of amioadore and BB can be explained by several reasons. In the case of amiodarone, it can be explained by fear of adverse reactions that may be expressed after a prolonged use of the medicament. In the case of BB, another contributor is the vastly available negative information regarding this group of drugs coming from different sources as well as not seeking proper information instead.
Analysing the efficacy of antiarrhythmic drugs, the most effective medication still remains amiodarone, which showed a statistically significant superiority over etacizine and propafenone (41.7% vs 71.4% vs 81.3%) (p = 0.02). The data has limitations, because in our study we did not analyse patients enrolled in another study comparing a combination of etacizine and beta-blockers to amiodarone, in which the combination showed a superiosity to amiodarone.
Examining the risk factors contributing to recurrence, with statistical significance the recurrence presented more often in patients with previously known AFib. Without statistical significance, the recurrence was more often in patients suffering from diabetes and congestive heart disease as well as in smokers, which corresponds to previous data . This can be explained by the induced atrial remodelation in patients with these conditions, as structural changes in myocardium lead to local heterogenity of electrical conduction, which can lead to re-entry mechanism and arhythmia.
Observed adverse reactions after six months were: six (3.6%) patients reported nausea, four (2.4%) had minor bleeding, six (3.6%) had cough and six (3.6%) had oedema. The frequency of bleeding caused by antithrombotic agents in our study was found to be lower than reflected in world literature (Camm et al., 2014; Femia et al., 2017) . Only 2.4% of patients complained about minor bleeding and none of the patients experienced serious, life-threatening bleeding.
CONCLUSIONS
The most commonly used and most effective medication was amiodarone. When comparing the data of patients over four years, the use of anticoagulants increased by 11.6% and the use of DOACs increased by 18.7%. Although 77.1% of patients taking aspirin had a CHADS-VASc ³ 2, there was still a group of patients taking aspirin instead of anticoagulants, which does not lower the risk of developing thrombembolism. The main reasons for non-compliance were fear of adverse drug reactions, high drug costs as well as negative information regarding the drugs coming from unauthorised sources. With statistical significance recurrence was higher in patients with previously known AFib. 30% patients of the study population did not know that Xarelto must be taken on an empty stomach, which could lead to thrombembolic events. The number of asymptomatic AFib patients was consistent with global data.
